Trader consensus heavily favors no new COVID variant of concern before 2027, reflecting the absence of any SARS-CoV-2 lineage meeting WHO or ECDC VOC criteria as of mid-2026. Ongoing surveillance tracks sublineages such as BA.3.2 (Cicada), NB.1.8.1 (Nimbus), and XFG (Stratus) as variants under monitoring, yet none demonstrate the combination of substantially increased transmissibility, severity, or immune escape needed for escalation. BA.3.2, first noted in late 2024, has spread to over 20 countries with localized rises in some European sequences but remains low-prevalence overall, without driving excess hospitalizations or vaccine failure. Updated 2025-2026 vaccines target recent JN.1 descendants, and global case trends show continued Omicron-family circulation without disruptive shifts. With roughly four months remaining in 2026, the low probability of rapid evolution crossing the VOC threshold underpins the strong "No" pricing.